Spark Biomedical, Inc.

Spark Biomedical, Inc. is a United States medical device company headquartered in Dallas, Texas, focused on bioelectronic medicine. The company designs and commercializes wearable neurostimulation devices that deliver Transcutaneous Auricular Neurostimulation (tAN), a non-invasive, drug-free therapy that targets the vagus and trigeminal nerves through the ear. Its flagship clinical application is the relief of opioid withdrawal symptoms in patients with Addiction Disorders, an area where the company positions its technology as an alternative or complement to traditional pharmaceutical and surgical therapies. Spark Biomedical's core product line is built around FDA-cleared wearable devices that provide targeted, on-demand electrical stimulation. According to the company, the devices are designed to be used across the full continuum of care — inpatient, outpatient, and at-home follow-on care — giving treatment facilities, care teams, and patients flexible options. The company markets the therapy under the "Sparrow" name, and patient testimonials on its website describe positive experiences using Sparrow therapy to manage opioid dependence. The company describes its purpose as "Better Options, Better Outcomes," framing itself as an agent of change in healthcare by advancing bioelectronic medicine that leverages the human nervous system. Spark Biomedical states that its solutions are designed and developed by a team with a combined 300 years of medical device expertise, spanning medicine, bioscience, patient care and advocacy, technology innovation, care coordination, and communications. Its leadership includes Chief Executive Officer Anja Kramer, Chief Science Officer and co-founder Navid Khodaparast, PhD, Chief Technical Officer and co-founder Alejandro Covalin, PhD, Chief Financial Officer Ric Peterson, and Executive Vice President of Growth Tom Futch. Spark Biomedical operates primarily in the United States market, serving addiction treatment providers and their patients. The company is privately held and is not known to be listed on a public stock exchange. Its identity is that of a clinical-stage-to-commercial medical technology brand rather than a consumer product brand, and its public communications emphasize regulatory clearance, clinical utility, and real-world treatment success stories from leading treatment facilities.

Spark Biomedical, Inc. is a medical device company based in Dallas, Texas, United States. The company was founded by Navid Khodaparast, PhD, and Alejandro Covalin, PhD, who today serve as Chief Science Officer and Chief Technical Officer respectively. The precise founding year is not stated in the available evidence. The company emerged in the field of bioelectronic medicine, an area of medical technology that uses electrical stimulation of the nervous system to treat disease, and it chose to focus on Addiction Disorders — specifically opioid withdrawal — as its first major clinical target. Spark Biomedical's technological foundation is Transcutaneous Auricular Neurostimulation (tAN), a non-invasive technique that delivers low-level electrical impulses through the skin of the ear to stimulate the vagus and trigeminal nerves. These two nerves are described by the company as key central control switches for the nervous system. By modulating neural pathways, the therapy is intended to counter harmful impulses, reduce discomfort, and help the body maintain physiological balance. The company developed this approach into FDA-cleared wearable devices, which it markets as Spark Wearable Neurostimulation and under the "Sparrow" therapy name. The company's stated purpose is "Better Options, Better Outcomes." It positions itself as an agent of change in a healthcare landscape that is "always changing, evolving, and expanding," and it describes its mission as creating "groundbreaking science that makes sense" — advancing bioelectronic medicine to address critical health needs such as Addiction Disorders. Spark Biomedical emphasizes that its devices enable treatment in every setting, including inpatient, outpatient, and at-home follow-on care, giving care providers and patients options beyond traditional drug therapies. According to the company, its wearable neurostimulation solutions are designed and developed by a team with a combined 300 years of medical device expertise. The team includes professionals in medicine, bioscience, patient care and advocacy, technology innovation, care coordination, and communications. The company states that leading treatment facilities already use its wearable neurostimulation solutions, and it publishes patient testimonials describing successful use of Sparrow therapy for opioid dependence. Spark Biomedical is privately held and headquartered in Dallas. Its leadership team includes CEO Anja Kramer, CSO and co-founder Navid Khodaparast, CTO and co-founder Alejandro Covalin, CFO Ric Peterson, and EVP of Growth Tom Futch. The company operates primarily in the United States market, serving addiction treatment providers and patients. Its public identity is that of a clinical and commercial medical technology brand focused on drug-free, non-invasive neurostimulation for addiction and related conditions.

• Spark Biomedical founded by Navid Khodaparast and Alejandro Covalin (exact year not stated in available evidence).

• Company develops Transcutaneous Auricular Neurostimulation (tAN) technology targeting the vagus and trigeminal nerves.

• FDA-cleared wearable neurostimulation devices commercialized for opioid withdrawal relief.

• Sparrow therapy adopted by leading treatment facilities, with patient success stories published.

Developer of FDA-cleared, non-invasive, drug-free wearable neurostimulation devices for addiction disorders and opioid withdrawal, positioned as an alternative to traditional drug and surgical therapies.

• Spark Wearable Neurostimulation

  FDA-cleared wearable devices delivering transcutaneous auricular neurostimulation (tAN) for drug-free treatment of opioid withdrawal.

• Sparrow therapy

  Branded therapy system using Spark wearable neurostimulation, cited in patient testimonials for opioid dependence.

1. 1Spark Biomedical Transcutaneous Auricular Neurostimulation for Opioid Withdrawal Reliefsparkbiomedical.com
2. 2About Spark Biomedical | Pioneering Wearable Neurostimulation Solutionssparkbiomedical.com
3. 3Pioneering Transcutaneous Auricular Neurostimulation | Spark Biomedicalsparkbiomedical.com
4. 4Spark Biomedical, Inc. (United States) - Wikidatawikidata.org